Sab Biotherapeutics Stock Revenue
| SABS Stock | USD 1.75 0.01 0.57% |
SAB Biotherapeutics fundamentals help investors to digest information that contributes to SAB Biotherapeutics' financial success or failures. It also enables traders to predict the movement of SAB Stock. The fundamental analysis module provides a way to measure SAB Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SAB Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 2 M | 1.9 M |
SAB | Revenue |
SAB Biotherapeutics Company Revenue Analysis
SAB Biotherapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current SAB Biotherapeutics Revenue | 2.24 M |
Most of SAB Biotherapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of SAB
Projected quarterly revenue analysis of SAB Biotherapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of SAB Biotherapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in SAB Biotherapeutics' stock price.
SAB Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Revenue. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.
| -0.24 | 0.86 | -0.58 | -0.18 | -0.99 | ||
| -0.24 | -0.14 | 0.36 | 0.99 | 0.37 | ||
| 0.86 | -0.14 | -0.14 | -0.13 | -0.85 | ||
| -0.58 | 0.36 | -0.14 | 0.26 | 0.61 | ||
| -0.18 | 0.99 | -0.13 | 0.26 | 0.31 | ||
| -0.99 | 0.37 | -0.85 | 0.61 | 0.31 |
Click cells to compare fundamentals
SAB Revenue Historical Pattern
Today, most investors in SAB Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various SAB Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of SAB Biotherapeutics revenue as a starting point in their analysis.
SAB Biotherapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
SAB Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, SAB Biotherapeutics reported 2.24 M of revenue. This is 99.97% lower than that of the Biotechnology sector and 99.7% lower than that of the Health Care industry. The revenue for all United States stocks is 99.98% higher than that of the company.
SAB Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in revenue category among its peers.
SAB Biotherapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in SAB Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of SAB Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing SAB Biotherapeutics' value.| Shares | First Premier Bank | 2024-12-31 | 19 K | Kestra Advisory Services, Llc | 2024-12-31 | 11.9 K | Northern Trust Corp | 2024-12-31 | 11.4 K | Citadel Advisors Llc | 2024-09-30 | 10.3 K | Ubs Group Ag | 2024-12-31 | 1.1 K | Tower Research Capital Llc | 2024-12-31 | 842 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 599 | Jpmorgan Chase & Co | 2024-09-30 | 212 | Gs Investment Inc | 2024-12-31 | 200 | Bvf Inc | 2024-12-31 | 917.8 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 459.2 K |
SAB Fundamentals
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Current Valuation | (9.87 M) | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 28.68 % | ||||
| Number Of Shares Shorted | 118.41 K | ||||
| Price To Book | 0.43 X | ||||
| Price To Sales | 10.68 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (25.38 M) | ||||
| EBITDA | (38.13 M) | ||||
| Net Income | (42.19 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 5.91 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 4.00 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Short Ratio | 0.63 X | ||||
| Earnings Per Share | (6.35) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 57 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 16.15 M | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
| Net Asset | 83.94 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.